Literature DB >> 1717573

Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies.

A Cerino1, M U Mondelli.   

Abstract

Several EBV-transformed B cell lines (BCL) were obtained from two patients with chronic hepatitis C virus (HCV) infection that secreted IgG class antibodies to the HCV nonstructural Ag c100-3. Two cloned BCL, derived from the same parental line, generated stable cloned lines that secreted up to 20 mg/liter of specific IgG1(kappa). Supernatants from oligoclonal and cloned BCL were also analyzed by immunoblot and all strongly reacted with recombinant polypeptides derived from the putative NS4 region of HCV, c100-3 and 5-1-1 (a 42-amino acid fragment of c100-3), whereas no reaction with the viral nucleoprotein, the NS3 nonstructural protein or the superoxide dismutase moiety of the c100-3 fusion protein could be documented. The fine specificity of these antibodies was also evaluated using overlapping synthetic peptides (20-mers) covering the 5-1-1 sequence. All oligoclonal and clonal IgG displayed high affinity binding to peptides covering residues 120-137 of Chiron's c100-3 sequence at the aminoterminus of 5-1-1. In addition, a minimal B cell epitope, N-VLYREF-C, was defined by human oligoclonal and monoclonal antibodies corresponding to residues 132-137. Interestingly, predominant recognition of the N-terminus of 5-1-1 was also observed in more than 80% of sera from patients with HCV infection. In conclusion, we have successfully produced human B cell cloned lines that secrete abundant quantities of IgG1(kappa)-specific for a polypeptide encoded by the NS4 region of HCV. Such antibodies recognize an immunodominant epitope, relative to this region, located at the N-terminus of the 5-1-1 fragment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717573

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

2.  Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

3.  Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C.

Authors:  R P González-Peralta; J W Fang; G L Davis; R G Gish; M Kohara; M U Mondelli; M S Urdea; M Mizokami; J Y Lau
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

4.  Significance of the immune response to a major, conformational B-cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody.

Authors:  M U Mondelli; A Cerino; P Boender; P Oudshoorn; J Middeldorp; C Fipaldini; N La Monica; W Habets
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity.

Authors:  Antonella Cerino; Corinna M Bremer; Dieter Glebe; Mario U Mondelli
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

6.  Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection.

Authors:  Antonella Cerino; Stefania Mantovani; Dalila Mele; Barbara Oliviero; Stefania Varchetta; Mario U Mondelli
Journal:  Front Immunol       Date:  2019-09-25       Impact factor: 7.561

7.  The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication.

Authors:  Brett D Lindenbach; Béla M Prágai; Roland Montserret; Rudolf K F Beran; Anna M Pyle; François Penin; Charles M Rice
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.